Chimerix (NASDAQ:CMRX) Announces Earnings Results, Hits Expectations

Chimerix (NASDAQ:CMRX) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23), Zacks reports. The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $1.26 million. Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. During the same quarter in the previous year, the company posted ($0.21) EPS.

Chimerix Price Performance

CMRX stock traded up $0.03 during trading on Wednesday, reaching $0.80. The company had a trading volume of 80,892 shares, compared to its average volume of 308,553. Chimerix has a 52 week low of $0.75 and a 52 week high of $1.30. The business has a 50 day moving average of $0.88 and a 200 day moving average of $0.97. The company has a market cap of $71.54 million, a P/E ratio of -0.83 and a beta of 1.20.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CMRX shares. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research note on Tuesday. StockNews.com cut Chimerix from a “hold” rating to a “sell” rating in a research note on Tuesday.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.